Back to Search
Start Over
Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
- Source :
-
Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2022 Jan; Vol. 169, pp. 103564. Date of Electronic Publication: 2021 Nov 30. - Publication Year :
- 2022
-
Abstract
- Fusions of NTRK (neurotrophic tyrosine receptor kinase) genes with 5' partner genes can result in the expression of chimeric proteins that drive oncogenesis through ligand-independent kinase activation. Despite variable frequencies of NTRK fusions in different tumor types, the fact that they are common to a wide range of cancers raises the possibility of developing tumor-agnostic treatments specifically targeting NTRK fusion products, irrespective of tumor type. The first-generation Trk (tropomyosin receptor kinase) inhibitor, larotrectinib, was the first tumor-agnostic treatment of NTRK fusion-positive cancers in adults and children, to be approved in the European Union. This consensus, developed by a Belgian multidisciplinary expert panel, aims to highlight the unmet medical need associated to NTRK fusion-driven cancer treatment and, based on current knowledge of NTRK fusions and larotrectinib treatment outcome and safety, provide comprehensive guidance to oncologists regarding NTRK fusion-driven cancer diagnostics and the best use of larotrectinib in real-world clinical settings.<br /> (Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1879-0461
- Volume :
- 169
- Database :
- MEDLINE
- Journal :
- Critical reviews in oncology/hematology
- Publication Type :
- Academic Journal
- Accession number :
- 34861380
- Full Text :
- https://doi.org/10.1016/j.critrevonc.2021.103564